Skip to content
Search

Latest Stories

Wes Streeting commits to unveiling men’s health strategy next year

UK to launch first men’s health strategy next year
(Getty Images)

The strategy will focus on preventing and addressing  the biggest health problems affecting men

Health secretary Wes Streeting has announced plans to introduce the UK’s first men’s health strategy at a Men’s Health Summit, held in partnership with Movember and hosted by Arsenal Football Club and the Premier League.

This strategy, which will be a key component of the government’s 10-Year Health Plan to fix the NHS, will be designed to address the biggest health problems affecting men, including cardiovascular disease, prostate and testicular cancer, mental health issues, and suicide prevention.


According to the Department of Health and Social Care (DHSC), a call for evidence will invite public feedback on “what is working and what more needs to be done to close the life expectancy gap between men and women.”

During the summit at Arsenal Football Club, Streeting met with campaigners from organisations like the UK Men’s Sheds Association, Prostate Cancer UK, and the African Advocacy Foundation, to discuss the obstacles men face in healthcare.

Streeting expressed particular concern over the rising rates of mental health issues and the shocking fact that suicide is “the biggest killer for men under the age of 50.”

He also highlighted the delayed diagnosis of preventable conditions such as heart disease and prostate cancer.

“Just as we are determined to end the injustices women face in healthcare, we won’t shy away from the need to focus on men’s health too,” he said, promising that the government would publish a men’s health strategy to tackle these problems head-on.

The DHSC confirmed that the strategy will be unveiled next year, with the call for evidence opening soon.

In addition, men are encouraged to give their views on building an NHS fit for the future through the Change NHS online portal.

Michelle Terry, CEO of Movember, welcomed the announcement, calling it “a significant step forward in transforming the face of men’s health.”

Emphasising the importance of a men’s health strategy, she said: “When we improve men’s health, we know that the benefits can ripple through families, communities, societies and the economy.

“This will transform the lives of men, but also their wives, mothers, sisters, partners, mates, neighbours, children, teachers and doctors.”

On average, men die nearly four years earlier than women and are more likely to be affected by conditions such as heart disease, cancer, and type 2 diabetes.

Heart disease is the leading cause of death for men in England, and significantly more men die early from cardiovascular disease compared to women.

Furthermore, men are less likely to seek help for mental health issues and account for three of four suicides.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less